Immuron Limited (IMRN): Price and Financial Metrics
Immuron Limited (IMRN)
Today's Latest Price: $3.40 USD
0.11 (-3.24%)
Updated Nov 18 6:55pm
Add IMRN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
IMRN Stock Summary
- IMRN has a market capitalization of $13,669,315 -- more than approximately just 6.03% of US stocks.
- The ratio of debt to operating expenses for Immuron Ltd is higher than it is for about only 0.39% of US stocks.
- With a year-over-year growth in debt of -100%, Immuron Ltd's debt growth rate surpasses just 0% of about US stocks.
- Stocks that are quantitatively similar to IMRN, based on their financial statements, market capitalization, and price volatility, are STIM, UG, CPST, DBD, and CPIX.
- IMRN's SEC filings can be seen here. And to visit Immuron Ltd's official web site, go to www.immuron.com.
IMRN Daily Price Range
IMRN 52-Week Price Range
IMRN Stock Price Chart More Charts
IMRN Price/Volume Stats
| Current price | $3.40 |
| Prev. close | $3.51 |
| Day low | $3.34 |
| Day high | $3.42 |
| 50-day MA | $3.14 |
| 200-day MA | $4.38 |
| 52-week high | $8.79 |
| 52-week low | $2.23 |
| Volume | 5,100 |
| Avg. volume | 102,205 |
| Dividend yield | N/A |
| Market Cap | 12.17M |
Immuron Limited (IMRN) Company Bio
Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.
Top Stories View All
Best & Worst Performing Stock Industries for November 18, 2019
Best & Worst Performing Small Cap Stocks for November 18, 2019
Best & Worst Performing Mid Cap Stocks for November 18, 2019
Best & Worst Performing Large Cap Stocks for November 18, 2019
Best & Worst Performing Mega Cap Stocks for November 18, 2019
View All Top Stories
Loading social stream, please wait...